Targeting NaPi2b in ovarian cancer.
View/ Open
Date
2023-01-01ICR Author
Author
Banerjee, S
Drapkin, R
Richardson, DL
Birrer, M
Type
Journal Article
Metadata
Show full item recordAbstract
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particularly in the platinum-resistant setting. NaPi2b is a cell surface sodium-dependent phosphate transporter that regulates phosphate homeostasis under normal physiological conditions and is a lineage marker that is expressed in select cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. Based on its increased expression in ovarian tumors, NaPi2b is a promising candidate to be studied as a biomarker for treatment and patient selection in ovarian cancer. In preclinical studies, the use of antibodies against NaPi2b showed that this protein can be exploited for tumor mapping and therapeutic targeting. Emerging data from phase 1 and 2 clinical trials in ovarian cancer have suggested that NaPi2b can be successfully detected in patient biopsy samples using immunohistochemistry, and the NaPi2b-targeting antibody-drug conjugate under evaluation appeared to elicit therapeutic responses. The aim of this review is to examine literature supporting NaPi2b as a novel biomarker for potential treatment and patient selection in ovarian cancer and to discuss the critical next steps and future analyses necessary to drive the study of this biomarker and therapeutic targeting forward.
Collections
Subject
Antibody-drug conjugate
Biomarker
Ovarian cancer
Humans
Female
Ovarian Neoplasms
Immunohistochemistry
Breast Neoplasms
Biomarkers
Immunoconjugates
Platinum
Language
eng
Date accepted
2022-11-09
License start date
2023-01-01
Citation
Cancer Treatment Reviews, 2023, 112 pp. 102489 -
Publisher
ELSEVIER SCI LTD